| Tumor cells can follow distinct evolutionary paths to become resistant to epidermal growth factor receptor inhibition AN Hata, MJ Niederst, HL Archibald, M Gomez-Caraballo, FM Siddiqui, ... Nature medicine 22 (3), 262-269, 2016 | 951 | 2016 |
| Patient-derived models of acquired resistance can identify effective drug combinations for cancer AS Crystal, AT Shaw, LV Sequist, L Friboulet, MJ Niederst, EL Lockerman, ... Science 346 (6216), 1480-1486, 2014 | 798 | 2014 |
| The BCL2 family: key mediators of the apoptotic response to targeted anticancer therapeutics AN Hata, JA Engelman, AC Faber Cancer discovery 5 (5), 475-487, 2015 | 647 | 2015 |
| Acquired resistance to EGFR tyrosine kinase inhibitors in cancer cells is mediated by loss of IGF-binding proteins M Guix, AC Faber, SE Wang, MG Olivares, Y Song, S Qu, C Rinehart, ... The Journal of clinical investigation 118 (7), 2609-2619, 2008 | 635 | 2008 |
| Synthetic lethal interaction of combined BCL-XL and MEK inhibition promotes tumor regressions in KRAS mutant cancer models RB Corcoran, KA Cheng, AN Hata, AC Faber, H Ebi, EM Coffee, ... Cancer cell 23 (1), 121-128, 2013 | 409 | 2013 |
| Differential induction of apoptosis in HER2 and EGFR addicted cancers following PI3K inhibition AC Faber, D Li, YC Song, MC Liang, BY Yeap, RT Bronson, E Lifshits, ... Proceedings of the National Academy of Sciences 106 (46), 19503-19508, 2009 | 353 | 2009 |
| BIM expression in treatment-naive cancers predicts responsiveness to kinase inhibitors AC Faber, RB Corcoran, H Ebi, LV Sequist, BA Waltman, E Chung, J Incio, ... Cancer discovery 1 (4), 352-365, 2011 | 331 | 2011 |
| An ErbB3 antibody, MM-121, is active in cancers with ligand-dependent activation B Schoeberl, AC Faber, D Li, MC Liang, K Crosby, M Onsum, ... Cancer research 70 (6), 2485-2494, 2010 | 330 | 2010 |
| PI3K regulates MEK/ERK signaling in breast cancer via the Rac-GEF, P-Rex1 H Ebi, C Costa, AC Faber, M Nishtala, H Kotani, D Juric, P Della Pelle, ... Proceedings of the National Academy of Sciences 110 (52), 21124-21129, 2013 | 240 | 2013 |
| Measurement of PIP3 levels reveals an unexpected role for p110β in early adaptive responses to p110α-specific inhibitors in luminal breast cancer C Costa, H Ebi, M Martini, SA Beausoleil, AC Faber, CT Jakubik, A Huang, ... Cancer cell 27 (1), 97-108, 2015 | 207 | 2015 |
| Epithelial-to-Mesenchymal Transition Defines Feedback Activation of Receptor Tyrosine Kinase Signaling Induced by MEK Inhibition in KRAS-Mutant Lung Cancer H Kitai, H Ebi, S Tomida, KV Floros, H Kotani, Y Adachi, S Oizumi, ... Cancer discovery 6 (7), 754-769, 2016 | 170 | 2016 |
| TORC1 suppression predicts responsiveness to RAF and MEK inhibition in BRAF-mutant melanoma RB Corcoran, SM Rothenberg, AN Hata, AC Faber, A Piris, RM Nazarian, ... Science translational medicine 5 (196), 196ra98-196ra98, 2013 | 152 | 2013 |
| mTOR Inhibition Specifically Sensitizes Colorectal Cancers with KRAS or BRAF Mutations to BCL-2/BCL-XL Inhibition by Suppressing MCL-1 AC Faber, EM Coffee, C Costa, A Dastur, H Ebi, AN Hata, AT Yeo, ... Cancer discovery 4 (1), 42-52, 2014 | 143 | 2014 |
| Assessment of ABT-263 activity across a cancer cell line collection leads to a potent combination therapy for small-cell lung cancer AC Faber, AF Farago, C Costa, A Dastur, M Gomez-Caraballo, R Robbins, ... Proceedings of the National Academy of Sciences 112 (11), E1288-E1296, 2015 | 139 | 2015 |
| Exploitation of the apoptosis-primed state of MYCN-amplified neuroblastoma to develop a potent and specific targeted therapy combination J Ham, C Costa, R Sano, TL Lochmann, EM Sennott, NU Patel, A Dastur, ... Cancer cell 29 (2), 159-172, 2016 | 127 | 2016 |
| Activation of PI3K signaling in Merkel cell carcinoma V Nardi, Y Song, JA Santamaria-Barria, AK Cosper, Q Lam, AC Faber, ... Clinical Cancer Research 18 (5), 1227-1236, 2012 | 127 | 2012 |
| Clearance of therapy‐induced senescent tumor cells by the senolytic ABT‐263 via interference with BCL‐XL–BAX interaction T Saleh, VJ Carpenter, L Tyutyunyk‐Massey, G Murray, JD Leverson, ... Molecular oncology 14 (10), 2504-2519, 2020 | 126 | 2020 |
| Venetoclax is effective in small-cell lung cancers with high BCL-2 expression TL Lochmann, KV Floros, M Naseri, KM Powell, W Cook, RJ March, ... Clinical cancer research 24 (2), 360-369, 2018 | 123 | 2018 |
| Emergence and spread of carbapenem-resistant Acinetobacter baumannii international clones II and III in Lima, Peru S Levy-Blitchtein, I Roca, S Plasencia-Rebata, W Vicente-Taboada, ... Emerging microbes & infections 7 (1), 1-9, 2018 | 110 | 2018 |
| Failure to induce apoptosis via BCL-2 family proteins underlies lack of efficacy of combined MEK and PI3K inhibitors for KRAS-mutant lung cancers AN Hata, A Yeo, AC Faber, E Lifshits, Z Chen, KA Cheng, Z Walton, ... Cancer research 74 (11), 3146-3156, 2014 | 101 | 2014 |
